Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-03 @ 8:15 AM
Study NCT ID:
NCT03722420
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-28
First Post:
2018-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Sponsor:
Il-Yang Pharm. Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
RT51CN03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None